RxDoctor Payments Data

Sisom Osia, MD

Internal Medicine · Upper Marlboro, MDNPI 1154442366

Payments from drug & device makers

$1,666in general payments, 2019–2025

Across 66 payments — averaging $25.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$630
  • AstraZeneca$537
  • Lilly USA, LLC$180
  • Abbott$78
  • Bayer$75
  • Dexcom, Inc.$69
  • plus $97 from 3 others

What the payments were for

  • Food & beverage$1,666100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,666 in reported general payments places this provider in the 75th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$24,900
Medicare patients
97
Services billed
218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide47$71,907
EliquisApixaban27$28,893
JanuviaSitagliptin Phosphate15$9,207
Tresiba Flextouch U-200Insulin Degludec12$9,035
Nisoldipine13$5,990
Colchicine15$1,766
Nifedipine ErNifedipine46$1,338
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide29$1,119
Atorvastatin Calcium86$945
Amlodipine-ValsartanAmlodipine Besylate/Valsartan22$912
Amlodipine Besylate143$874
Metoprolol Succinate49$736
Albuterol Sulfate HfaAlbuterol Sulfate23$724
Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril30$723
Losartan Potassium75$713

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$630$71,90747 claims
PfizerEliquis$41$28,89327 claims
Lilly USA, LLCHumulin 70-30$180$48012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Upper Marlboro

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →